Get the Stockscreener App
114.55
2.81%
-3.31
After Hours:
115.00
0.45
+0.39%
Overview
News
Price History
Option Chain
Financials
Why GILD Down?
Discussions
Forecast
Stock Split
Dividend History
Gilead Sciences Inc stock is traded at $114.55, with a volume of 6.47M.
It is down -2.81% in the last 24 hours and down -4.56% over the past month.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
See More
Previous Close:
$117.86
Open:
$117.49
24h Volume:
6.47M
Relative Volume:
0.99
Market Cap:
$142.13B
Revenue:
$28.80B
Net Income/Loss:
$6.31B
P/E Ratio:
22.82
EPS:
5.02
Net Cash Flow:
$9.37B
1W Performance:
-0.43%
1M Performance:
-4.56%
6M Performance:
+0.49%
1Y Performance:
+37.75%
1-Day Range:
$114.17
$117.63
1-Week Range:
$113.82
$118.11
52-Week Range:
$81.57
$121.83
Gilead Sciences Inc Stock (GILD) Company Profile
Name
Gilead Sciences Inc
Sector
Industry
Phone
(650) 574-3000
Address
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
114.55 | 143.00B | 28.80B | 6.31B | 9.37B | 5.02 |
|
LLY
Lilly Eli Co
|
755.39 | 676.48B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
178.06 | 423.36B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
218.34 | 373.87B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
124.12 | 244.98B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
82.81 | 209.89B | 63.43B | 16.42B | 14.72B | 6.49 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Aug-08-25 | Upgrade | Truist | Hold → Buy |
| Jul-25-25 | Upgrade | Needham | Hold → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-04-25 | Reiterated | Oppenheimer | Outperform |
| Feb-18-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-13-25 | Upgrade | DZ Bank | Hold → Buy |
| Jan-10-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Nov-08-24 | Downgrade | Maxim Group | Buy → Hold |
| Oct-21-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-07-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-08-24 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-24 | Reiterated | Maxim Group | Buy |
| Apr-24-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Feb-22-24 | Downgrade | Truist | Buy → Hold |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Sep-08-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-06-23 | Initiated | HSBC Securities | Reduce |
| Jul-24-23 | Reiterated | Barclays | Equal Weight |
| May-16-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-28-23 | Resumed | Piper Sandler | Overweight |
| Jan-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-13-22 | Resumed | BofA Securities | Neutral |
| Dec-09-22 | Downgrade | DZ Bank | Buy → Hold |
| Oct-31-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-28-22 | Reiterated | BMO Capital Markets | Market Perform |
| Oct-28-22 | Reiterated | Cowen | Outperform |
| Oct-28-22 | Reiterated | JP Morgan | Overweight |
| Oct-28-22 | Reiterated | Jefferies | Buy |
| Oct-28-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-28-22 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-28-22 | Upgrade | Truist | Hold → Buy |
| Oct-28-22 | Reiterated | Wells Fargo | Equal Weight |
| Oct-04-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-28-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-02-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-02-22 | Reiterated | BofA Securities | Neutral |
| Feb-02-22 | Reiterated | RBC Capital Mkts | Outperform |
| Feb-02-22 | Reiterated | Truist | Hold |
| Feb-02-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Argus | Hold → Buy |
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-19-21 | Resumed | Piper Sandler | Neutral |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Jul-30-21 | Reiterated | BMO Capital Markets | Market Perform |
| Jul-30-21 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-01-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-30-21 | Upgrade | Redburn | Neutral → Buy |
| Jan-19-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-03-20 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Sep-30-20 | Resumed | Jefferies | Buy |
| Sep-15-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-31-20 | Reiterated | Credit Suisse | Neutral |
| Jul-31-20 | Reiterated | Morgan Stanley | Equal-Weight |
| Jul-31-20 | Reiterated | Piper Sandler | Overweight |
| Jul-31-20 | Reiterated | RBC Capital Mkts | Outperform |
| Jul-31-20 | Reiterated | SunTrust | Hold |
| Jul-31-20 | Reiterated | Wells Fargo | Equal Weight |
| Jul-20-20 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jun-03-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-26-20 | Upgrade | SunTrust | Sell → Hold |
| May-01-20 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-20 | Downgrade | SunTrust | Hold → Sell |
| Apr-27-20 | Downgrade | UBS | Buy → Neutral |
| Apr-20-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Apr-20-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Downgrade | CFRA | Hold → Sell |
View All
Gilead Sciences Inc Stock (GILD) Latest News
Here's How You Can Earn $100 In Passive Income By Investing In Gilead Sciences Stock - Yahoo Finance
Gilead beats whistleblower lawsuit over hepatitis C drugs - Reuters
Gilead prevails in whistleblower lawsuit over alleged hepatitis C prescription kickbacks - Fierce Pharma
Gilead Sciences, Inc. $GILD Shares Sold by Intech Investment Management LLC - MarketBeat
Gilead Defeats Whistleblower’s Hepatitis C Drug Kickback Lawsuit - Bloomberg Law News
Ilmarinen Mutual Pension Insurance Co Raises Position in Gilead Sciences, Inc. $GILD - MarketBeat
Glenview Trust co Increases Position in Gilead Sciences, Inc. $GILD - MarketBeat
Rothschild & Co Redburn Adjusts Gilead Sciences Price Target to $143 From $136, Maintains Buy Rating - MarketScreener
Gilead Sciences, Inc. : The underlying trend is in force again - MarketScreener
Gilead Sciences, Inc. $GILD Shares Acquired by Fred Alger Management LLC - MarketBeat
Gilead Sciences stock price target raised to $143 from $136 at Rothschild Redburn - Investing.com
Kestra Investment Management LLC Sells 2,391 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
State of Wyoming Decreases Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (GILD) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
Gilead Sciences Commits To Veeva Systems (VEEV) For Vault CRM Suite - simplywall.st
Ex-Dividend Reminder: Gilead Sciences, Thermo Fisher Scientific and Merck - Nasdaq
Sanofi wins big at the 2025 Fierce Pharma Marketing Awards - Fierce Pharma
Zurich Insurance Group Ltd FI Cuts Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Cinctive Capital Management LP Cuts Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Stock Position Boosted by Ascent Group LLC - MarketBeat
Gilead Sciences, Inc. $GILD Shares Acquired by Meiji Yasuda Life Insurance Co - MarketBeat
Continental Advisors LLC Decreases Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Voleon Capital Management LP Lowers Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Gotham Asset Management LLC - MarketBeat
SLB, Apple, Nvidia, Merck, Gilead Sciences: What Sparked Heavy After-Hours Trading In These 5 Stocks? - Stocktwits
Parkman Healthcare Partners LLC Cuts Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead, Moderna to see upside if RFK Jr. leaves HHS: RBC - MSN
Gilead at Baird Global Healthcare Conference: Expanding Cell Therapy Horizons - Investing.com
Gilead Sciences Commits to Veeva Vault CRM - Contract Pharma
Curi RMB Capital LLC Has $8.92 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences Commits to Veeva Vault Crm - MarketScreener
Should Income Investors Look At Gilead Sciences, Inc. (NASDAQ:GILD) Before Its Ex-Dividend? - 富途牛牛
Veeva Systems says Gilead Sciences commits to Veeva Vault CRM - MarketScreener
Gilead Sciences commits to Veeva Vault CRM - Investing.com
Veeva Systems Expands Partnership With Gilead Sciences - MarketScreener
Veeva Systems partners with Gilead for Vault CRM (VEEV:NYSE) - Seeking Alpha
Veeva Systems Gilead Sciences California - AD HOC NEWS
Gilead Sciences commits to Veeva Vault CRM platform - StreetInsider
Life Sciences Giant Gilead Sciences Adopts Veeva's Next-Gen AI-Powered CRM Platform for Commercial Operations - Stock Titan
Great Lakes Advisors LLC Grows Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead fashions new primary biliary cholangitis campaign alongside 'Project Runway' designer - Fierce Pharma
CTC Alternative Strategies Ltd. Makes New $784,000 Investment in Gilead Sciences, Inc. $GILD - MarketBeat
US Cystic Fibrosis Therapeutics Market Forecast and Company Analysis Report 2025-2033 Featuring Vertex, Abbvie, Novartis, Gilead Sciences, Viatris, Pfizer, AstraZeneca, and F. Hoffmann-La Roche - Yahoo Finance
Xilio Stock Jumps 8% On Cancer Drug Data; Gilead Boost Extends Cash Runway Into 2027 — Retail Says Stock Undervalued - MSN
Gilead Price Hikes Screw ADAP Programs, HIV Patients--AHF Protest - AIDS Healthcare Foundation
Gilead at Morgan Stanley Conference: Strategic Diversification Unveiled - Investing.com
What the Trump Administration Partnership Means for Gilead Sciences Shares in 2025 - Yahoo Finance
Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead - The Manila Times
Xilio Therapeutics Announces Initiation of Phase 2 Trial - GlobeNewswire
Promising Cancer Drug Shows Partial Responses: Xilio's IL-12 Therapy Advances with $17.5M Gilead Backing - Stock Titan
Teza Capital Management LLC Takes Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences Inc Stock (GILD) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.98%
1.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):